Cingulate (Cingulate) Debt-to-Equity : 0.13 (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Cingulate Debt-to-Equity?

Cingulate's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.39 Mil. Cingulate's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $0.03 Mil. Cingulate's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $3.22 Mil. Cingulate's debt to equity for the quarter that ended in Mar. 2024 was 0.13.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Cingulate's Debt-to-Equity or its related term are showing as below:

CING' s Debt-to-Equity Range Over the Past 10 Years
Min: -37.54 Med: 0.29 Max: 70.52
Current: 0.13

During the past 5 years, the highest Debt-to-Equity Ratio of Cingulate was 70.52. The lowest was -37.54. And the median was 0.29.

CING's Debt-to-Equity is ranked better than
52.9% of 1068 companies
in the Biotechnology industry
Industry Median: 0.14 vs CING: 0.13

Cingulate Debt-to-Equity Historical Data

The historical data trend for Cingulate's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cingulate Debt-to-Equity Chart

Cingulate Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

3.39

1.58

0.04

1.51

-0.51

Cingulate Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial												70.52	-1.37	-37.54	-0.51	0.13

Competitive Comparison of Cingulate's Debt-to-Equity

For the Biotechnology subindustry, Cingulate's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cingulate's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cingulate's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Cingulate's Debt-to-Equity falls into.

Cingulate Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Cingulate's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(3.375	+	0.135)	/	-6.869
	=	-0.51

Cingulate's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(0.39	+	0.033)	/	3.216
	=	0.13

Cingulate (NAS:CING) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Cingulate Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Cingulate's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Cingulate (Cingulate) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cingulate Inc (NAS:CING) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

1901 W. 47th Place, Kansas, KS, USA, 66205

Website

https://www.cingulate.com

Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.

Executives

Jennifer L. Callahan	officer: Corporate Controller	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Peter J. Werth	director, 10 percent owner	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Shane J. Schaffer	director, 10 percent owner, officer: Chief Executive Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Craig S. Gilgallon	officer: EVP & General Counsel	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Laurie Myers	officer: EVP & Chief Operating Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Gregg Wm Givens	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Scott Applebaum	director	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
Curtis Medeiros	director	2120 COLORADO AVE., SUITE 230, SANTA MONICA CA 90404
Van Horn Louis G	officer: EVP & Chief Financial Officer	C/O CINGULATE THERAPEUTICS, 1901 W. 47TH PLACE, THIRD FLOOR, KANSAS CITY KS 66205
Patrick Joseph Gallagher	director	275 PLEASANT HILL RD., FLANDERS NJ 07836
Jeffrey X Conroy	director	2372 MORSE AVE, IRVINE CA 92614
Thomas Jeffrey Hargroves	director	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Raul R. Silva	officer: EVP & Chief Science Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Matthew Brams	officer: EVP & Chief Medical Officer	C/O CINGULATE INC., 1901 W. 47TH PLACE, KANSAS CITY KS 66205
Fountainhead Shrugged, Llc	10 percent owner	1901 W. 47TH PLACE, #310, KANSAS CITY KS 66205